Prescient Therapeutics Are Developing Game-Changing Cancer Treatments

June 3, 2022

Prescient Therapeutics (ASX: PTX) Managing Director and Chief Executive Officer Steven Yatomi-Clarke joins ASX Investor to discuss the company’s innovative cancer treatments with the biotech company having a range of targeting therapies and their next generation CAR-T treatment called OmniCAR.

Watch the full interview below.

Related Post

×